Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transfer factor in immunodeficiency diseases.

L E Spitler

    Annals of the New York Academy of Sciences
    |January 1, 1979
    PubMed
    Summary
    This summary is machine-generated.

    Transfer factor shows promise in treating immunodeficiency diseases and melanoma by enhancing immune responses. Further controlled studies are needed to confirm its efficacy in specific patient groups.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma.

    Critical reviews in oncology/hematology·2001
    Same author

    Adjuvant therapy of melanoma: at what cost?

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
    Same author

    Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer.

    The Prostate·2001
    Same author

    Clinical experience with autologous tumor cell lines for patient-specific vaccine therapy in metastatic melanoma.

    Cancer biotherapy & radiopharmaceuticals·2000
    Same author

    Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2000
    Same author

    Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery.

    Journal of pharmaceutical sciences·1999
    Same journal

    Multiomics Profiling During Autoimmune Demyelination Highlights a Complex Regulatory Role for Ataxin-1 in B Cells.

    Annals of the New York Academy of Sciences·2026
    Same journal

    Global Trends in Light Pollution and Their Relationship With Socioeconomic Factors.

    Annals of the New York Academy of Sciences·2026
    Same journal

    Wired for Corruption: Inter-Brain Synchrony Encodes Bribery-Related Value Information and Predicts Bribery Agreement.

    Annals of the New York Academy of Sciences·2026
    Same journal

    LM-YOLO: A Lightweight Multi-Scale Enhanced Model for Forest Smoke Detection Using Unmanned Aerial Vehicles.

    Annals of the New York Academy of Sciences·2026
    Same journal

    Polyrhythm Perception and Production: A Scoping Review.

    Annals of the New York Academy of Sciences·2026
    Same journal

    DARTS-CNN-BiLSTM: Intelligent Fault Diagnosis for Computer Numerical Control Machine Tool Feed System.

    Annals of the New York Academy of Sciences·2026
    See all related articles

    Area of Science:

    • Immunology
    • Clinical Trials
    • Cellular Immunology

    Background:

    • Primary and secondary immunodeficiency diseases impair immune function.
    • Wiskott-Aldrich syndrome is a severe primary immunodeficiency.
    • Malignant melanoma, particularly at advanced stages, has a poor prognosis.

    Purpose of the Study:

    • To evaluate the clinical benefit and immunological enhancement of transfer factor therapy.
    • To assess the efficacy of transfer factor in Wiskott-Aldrich syndrome and malignant melanoma.
    • To investigate transfer factor's effect on immune reactivity in normal and immunodeficient subjects.

    Main Methods:

    • Therapeutic trials and long-term follow-up of patients with immunodeficiencies and melanoma.
    • Controlled, double-blind studies in human subjects.

    Related Experiment Videos

  • Development of a guinea pig model to study transfer factor's effect on immune tolerance.

    • Main Results:

    • Transfer factor suggests clinical benefit and enhanced immunological reactivity in patients with primary/secondary immunodeficiencies.
    • In Wiskott-Aldrich syndrome, transfer factor showed conversion of immunologic reactivity, clinical benefit, and prolonged survival in some patients.
    • Patients with Stage III malignant melanoma treated with transfer factor and surgery had improved survival rates (78% at 2 years).
    • Transfer factor did not enhance reactivity in normal subjects in controlled studies.
    • A guinea pig model demonstrated transfer factor's ability to abrogate tolerance.

    Conclusions:

    • Transfer factor demonstrates potential therapeutic benefits for certain immunodeficiency diseases and as an adjuvant therapy for malignant melanoma.
    • Further controlled studies in immunodeficient patients are required to confirm immune enhancement.
    • The guinea pig model provides a tool for investigating transfer factor's mechanisms of action.